Across TCGA pan-cancer cohorts, KAZN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KAZN data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KAZN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KAZN expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where KAZN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.844	0.632	.010	33	view →
LUAD	OS	Tertile	II,III,IV	0.848	0.352	.026	2	view →
UCEC	DFS	Median	All	1.000	0.939	.046	2	view →
GBM	OS	Quartile	All	0.285	0.529	.047	2	view →
LSCC	DFS	Quartile	II,III,IV	0.917	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KAZN tumor-vs-normal RNA expression · all KAZN data types